Metformin-based treatment for obesity-related hypertension: A randomized, double-blind, placebo-controlled trial

Journal of Hypertension

Volumn 30, Issue 7, 2012, Pages 1430-1439

  He, Hongbo ^a   Zhao, Zhigang ^a   Chen, Jing ^a   Ni, Yinxing ^a   Zhong, Jian ^a   Yan, Zhencheng ^a   Li, Yingsha ^a   Liu, Daoyan ^a   Pletcher, Mark J ^b   Zhu, Zhiming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

hypertension; inflammation; metabolism; metformin; obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; AMLODIPINE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CANDESARTAN; CHOLESTEROL; CREATINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; INSULIN; LACTIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; TELMISARTAN; UNCLASSIFIED DRUG; URIC ACID;

ABDOMINAL FAT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BODY WEIGHT; CHINA; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84862776132     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328353e249     Document Type: Article

References (47)

1. Singh GK, Siahpush M, Hiatt RA, Timsina LR. Dramatic increases in obesity and overweight prevalence and body mass index among ethnic-immigrant and social class groups in the United States, 1976-2008. J Community Health 2011; 36:94-110.
2. Reynolds K, Gu D, Whelton PK, Wu X, Duan X, Mo J, et al. Prevalence and risk factors of overweight and obesity in China. Obesity (Silver Spring) 2007; 15:10-18. (Pubitemid 46219778)
3. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009; 53:577-584.
4. Madec S, Chiarugi M, Santini E, Rossi C, Miccoli P, Ferrannini E, et al. Pattern of expression of inflammatory markers in adipose tissue of untreated hypertensive patients. J Hypertens 2010; 28:1459-1465.
5. Lakoski SG, Cushman M, Siscovick DS, Blumenthal RS, Palmas W, Burke G, et al. The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). J Hum Hypertens 2011; 25:73-79.
6. Aucott L, Gray D, Rothnie H, Thapa M, Waweru C. Effects of lifestyle interventions and long-term weight loss on lipid outcomes: a systematic review. Obes Rev 2011; 12:e412-e425.
7. Straznicky N, Grassi G, Esler M, Lambert G, Dixon J, Lambert E, et al. European Society of Hypertension Working Group on Obesity Antihypertensive effects of weight loss: myth or reality? J Hypertens 2010; 28:637-643.
8. Aucott L, Rothnie H, McIntyre L, Thapa M, Waweru C, Gray D. Longterm weight loss from lifestyle intervention benefits blood pressure?: a systematic review. Hypertension 2009; 54:756-762.
9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762. (Pubitemid 47356612)
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572. (Pubitemid 37430158)
11. Scholze J, Grimm E, Herrmann D, Unger T, Kintscher U. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007; 115:1991-1998. (Pubitemid 46625949)
12. Yancy WS Jr, Westman EC, McDuffie JR, Grambow SC, Jeffreys AS, Bolton J, et al. A randomized trial of a low-carbohydrate diet vs. orlistat plus a low-fat diet for weight loss. Arch Intern Med 2010; 170:136-145.
13. Ruilope LM, Despres JP, Scheen A, Pi-Sunyer X, Mancia G, Zanchetti A, et al. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens 2008; 26:357-367.
14. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363:905-917.
15. Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010; 376:517-523.
16. Food and Drug Administration. FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm. [Accessed 15 January 2012]
17. Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 2009; 46:113-118.
18. Wilson DM, Abrams SH, Aye T, Lee PD, Lenders C, Lustig RH, et al. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med 2010; 164:116-123.
19. Park MH, Kinra S, Ward KJ, White B, Viner RM. Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009; 32:1743-1745.
20. Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother 2008; 42:817-826. (Pubitemid 351778088)
21. Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006; 91: 2074-2080. (Pubitemid 43854985)
22. Charles MA, Eschwege E, Grandmottet P, Isnard F, Cohen JM, Bensoussan JL, et al. Treatment with metformin of nondiabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev 2000; 16:2-7. (Pubitemid 30160610)
23. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340:c869.
24. Snorgaard O, Kober L, Carlsen J. The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. J Intern Med 1997; 242:407-412. (Pubitemid 27513107)
25. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available from http://www.idf. org/webdata/docs/IDF- Metasyndrome-definition.pdf. [Accessed 15 January 2012]
26. Zhao Z, Nie H, He H, Yan Z, Liu D, Luo Z, et al. High-sensitivity C-reactive protein predicts target organ damage in Chinese patients with metabolic syndrome. Metabolism 2007; 56:1612-1619. (Pubitemid 350081042)
27. Hirooka M, Kumagi T, Kurose K, Nakanishi S, Michitaka K, Matsuura B, et al. A technique for the measurement of visceral fat by ultrasonography: comparison of measurements by ultrasonography and computed tomography. Intern Med 2005; 44:794-799. (Pubitemid 41263822)
28. Rankinen T, Kim SY, Perusse L, Despres JP, Bouchard C. The prediction of abdominal visceral fat level from body composition and anthropometry: ROC analysis. Int J Obes Relat Metab Disord 1999; 23:801-809. (Pubitemid 29378254)
29. He H, Ni Y, Chen J, Zhao Z, Zhong J, Liu D, et al. Sex difference in cardiometabolic risk profile and adiponectin expression in subjects with visceral fat obesity. Transl Res 2010; 155:71-77.
30. Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 2010; 23:1170-1178.
31. Schlaich MP, Grassi G, Lambert GW, Straznicky N, Esler MD, Dixon J, et al. European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions. J Hypertens 2009; 27:207-211.
32. Levri KM, Slaymaker E, Last A, Yeh J, Ference J, D'Amico F, et al. Metformin as treatment for overweight and obese adults: a systematic review. Ann Fam Med 2005; 3:457-461. (Pubitemid 41512664)
33. Zulian A, Cancello R, Girola A, Gilardini L, Alberti L, Croci M, et al. In vitro and in vivo effects of metformin on human adipose tissue adiponectin. Obes Facts 2011; 4:27-33.
34. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, During M, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009; 11:1163-1172.
35. Lee YC, Chang HH, Chiang CL, Liu CH, Yeh JI, Chen MF, et al. Role of perivascular adipose tissue-derived methyl palmitate in vascular tone regulation and pathogenesis of hypertension. Circulation 2011; 124: 1160-1171.
36. He H, Yang D, Ma L, Luo Z, Ma S, Feng X, et al. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways. Hypertension 2010; 55:869-879.
37. Muoio DM, Newgard CB. Metabolism: a is for adipokine. Nature 2005; 436:337-338. (Pubitemid 41059036)
38. Foy CG, Hsu FC, Haffner SM, Norris JM, Rotter JI, Henkin LF, et al. Visceral fat and prevalence of hypertension among African Americans and Hispanic Americans: findings from the IRAS family study. Am J Hypertens 2008; 21:910-916.
39. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116:39-48. (Pubitemid 47016245)
40. Carroll JF, Chiapa AL, Rodriquez M, Phelps DR, Cardarelli KM, Vishwanatha JK, et al. Visceral fat, waist circumference, and BMI: impact of race/ethnicity. Obesity (Silver Spring) 2008; 16:600-607. (Pubitemid 351337456)
41. Franks PW, Jablonski KA, Delahanty L, Hanson RL, Kahn SE, Altshuler D, et al. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia 2007; 50:2451-2460. (Pubitemid 350060645)
42. Fontbonne A, Diouf I, Baccara-Dinet M, Eschwege E, Charles MA. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in nondiabetic upper-body obese subjects with mild glucose anomalies: a posthoc analysis of the BIGPRO1 trial. Diabetes Metab 2009; 35:385-391.
43. Manzella D, Grella R, Esposito K, Giugliano D, Barbagallo M, Paolisso G. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. Am J Hypertens 2004; 17:223-227. (Pubitemid 38293326)
44. Brunani A, Caumo A, Graci S, Castagna G, Viberti G, Liuzzi A. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, nondiabetic patients. Diabetes Obes Metab 2008; 10:460-467. (Pubitemid 351639088)
45. Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H. Long term cardiovascular effects of oral antidiabetic agents in nondiabetic patients with insulin resistance: double blind, prospective, randomised study. Heart 2005; 91:589-594. (Pubitemid 40559346)
46. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007; 116:1234-1241. (Pubitemid 47517534)
47. Carter AM, Bennett CE, Bostock JA, Grant PJ. Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with type 2 diabetes mellitus. Diabet Med 2005; 22:1282-1284. (Pubitemid 41224195)